US And Canada

Crystal Amber could move to replace the board with a single appointee to drive through divestments, having already forced the resignation of former CEO Jill Smith.

Merck & Co will pay up to $773m to acquire biopharmaceutical developer Tilos Therapeutics, based on research at Harvard Medical School and Brigham & Women’s Hospital.

Lidar technology developer Sense Photonics has emerged from stealth with $26m in series A funding from investors co-led by the UC-backed Congruent Ventures.

Stanford spinout Tableau Software has agreed to a $15.7bn all-stock acquisition by Salesforce, six years after completing a $254m initial public offering on the New York Stock Exchange.

Artizan, a Yale University spinout focused on intestinal microbiota targets potentially responsible for inflammatory bowel disease, has been backed by investors including Brii Biosciences, bringing its total funding to $12m.

Allied Minds chief executive Jill Smith has seemingly been forced from her position under pressure from activist investor Crystal Amber.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

As MedWhat scores an initial win in its courtroom battle with Stanford, Paige.ai finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.

Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.

VW will invest $100m in QuantumScape and form a joint venture with the Stanford spinout to develop batteries for long-range electric vehicles.